Ignite Creation Date:
2025-12-24 @ 7:43 PM
Ignite Modification Date:
2025-12-25 @ 5:21 PM
Study NCT ID:
NCT01394003
Status:
TERMINATED
Last Update Posted:
2019-01-18
First Post:
2011-06-01
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Study of LY2584702 in Participants With Advanced Cancer
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
A Phase I Study of LY2584702 in Patient With Advanced or Metastatic Cancer
Status:
TERMINATED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The pharmacokinetic properties of the molecule do not allow for further dose escalation or development.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this trial is to determine a recommended Phase 2 dose of LY2584702 that may be safely administered to participants with advanced/metastatic cancer.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| I3G-MC-JGCA | OTHER | Eli Lilly and Company | View |